Navigation Links
Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results

Sixth Consecutive Quarter of Double-Digit Year-over-Year Revenue Increases from Antibody Technology (up 28%); Third Consecutive Quarter of More Than

20% Year-over-Year Growth in Food Pathogen Testing Business

NEWARK, Del., Feb. 28 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) - reported that total revenues for the quarter ended December 31, 2007, were $7.3 million, an increase of 4% over the fourth quarter of 2006. Revenues for the 2007 fourth quarter were positively impacted by a 28% increase in sales of antibody products and 21% growth in the sales of food pathogen testing methods, in both cases as compared to the fourth quarter of 2006. These increases were offset somewhat by the continuing decline in the Company's legacy U.S. Ag/GMO business of 65% as compared to the fourth quarter of 2006. Full-year total revenue increased 7% to $27.2 million versus $25.5 million for the same period in 2006.

Fourth Quarter and Recent Highlights

-- The Company's new, sequence-based, Genomic Antibody Technology(TM)

(GAT) platform continued to accelerate and earn market acceptance

within the life science industry as a proven tool for advancing

therapeutic and diagnostic product development efforts:

- Project bookings for "custom" GAT projects exceeded the

$1 million mark over the last seven months of 2007, following the

introduction of the full-range of GAT offerings during May 2007,

with more than half of these new projects booked during the

fourth quarter.

- The Company's new Internet-based catalog of proprietary,

SEQer(TM) brand antibody reagents was launched during thn disposal of assets 2 - 110 -

Total operating expenses 6,960 6,451 25,804 24,942

Operating income 311 539 1,403 580

Interest income (expense), net 98 111 433 386

Income before taxes 409 650 1,836 966

Income tax expense 243 159 976 282

Net income 166 491 860 684

Basic net income per share $0.01 $ 0.02 $0.04 $ 0.03

Shares used in computing

basic net income per

share 20,396,000 20,141,000 20,325,000 20,032,000

Diluted net income per

share $0.01 $ 0.02 $0.04 $ 0.03

Shares used in computing

diluted net income per

share 20,768,000 20,227,000 20,563,000 20,109,000

The accompanying notes are an integral part of these statements



(in thousands) (unaudited)

Twelve Months Ended

December 31,

2007 2006

Cash Flows from Operating Activities :

Net income $860 $684

Adjustments to reconcile net income to

net cash provided by (used in) operating

activities :

Depreciation and amortization 1,206 1,027

Stock Compensation Expense 430 277

Deferred income tax provision 773 124

Loss on disposal of fixed assets 93 42

(Increase) decrease in :

Receivables (432) (436)

Inventories (1,026) 34

Other current assets (29) (130)

Other assets (15) 26

Increase (decrease) in :

Accounts payable 28 77

Accrued expenses 411 16

Deferred Revenue (128) (74)

Non-current taxes payable 130 -

Net cash provided by operating activities 2,301 1,667

Cash Flows from Investing Activities :

Purchase of property and equipment (2,484) (1,023)

Purchase of intangible assets - (117)

Proceeds from sale / disposal of assets 2 29

Net cash used in investing activities (2,482) (1,111)

Cash Flows from Financing Activities :

Proceeds from exercise of incentive stock options 538 389

Proceeds from employee stock purchase plan 36 20

Proceeds from long and short term debt 2,000 -

Repayments on financing obligations (311) (211)

Net cash provided by financing activities 2,263 198

Effect of exchange rate changes on cash 14 129

Net increase (decrease) in Cash and Cash

Equivalents 2,096 883

Cash and Cash Equivalents, Beginning of Period 10,892 10,009

Cash and Cash Equivalents, End of Period $12,988 $10,892

Supplemental Cash Flow Disclosure :

Cash paid for taxes 233 (13)

Cash paid for interest 78 48

The accompanying notes are an integral part of these statements

Company Contact: Investor Contact:

Stan Fronczkowski Hayden Communications

Chief Financial Officer Brett Maas (

(302) 456-6789 (646) 536-7331

e third

quarter and content is being added weekly.

- Expansion of the Company's Molecular Biology Lab in Dallas and

its facility in Newark, Delaware in response to growth in demand

for both GAT and conventional hybridoma development. This follows

the expansion of the Company's Windham, Maine antibody production

facility during November 2007, which increased capacity for

polyclonal antibody production by 44%.

-- SDI reported the sixth consecutive quarter of double digit

year-over-year growth in the antibody business.

-- SDI reported the third consecutive quarter of more than 20%

year-over-year growth in the food pathogen testing products area.

Matthew H. Knight, the Company's President and Chief Executive Officer, commented, "SDI has emerged as an established leader in the production of high-value antibody-based reagents used in the diagnosis of disease, and our antibody business, based on our new Genomic Antibody Technology(TM), is gaining widespread adoption in proteomic research, as well as drug/biomarker discovery among academic, biotech and large pharmaceutical customers. We reported our sixth consecutive quarter of double-digit year-over-year revenue growth in antibody-related revenue and this part of our business is becoming an increasingly important component of our overall revenue and profitability. For the quarter, antibody revenues expanded to 53% of total revenue compared to 43% in the fourth quarter of 2006."

Financial Highlights

In 000s Q4 Q4

2007 2006

Revenues $7,271 $6,990

Gross Profit 4,396 3,902

SG&A Expense 3,329 2,692

R&D Expense 754 671

Operating Profit 311 539

Pre-tax Income 409 650

Net Income 166 491

In 000s Full Year Full Year

2007 2006

Revenues $27,207 $25,522

Gross Profit 16,441 13,801

SG&A Expense 11,990 10,591

R&D Expense 2,938 2,630

Operating Profit 1,403 580

Pre-tax Income 1,836 966

Net Income 860 684

The Company continued to demonstrate ongoing improvement in gross profit (defined as total revenue less manufacturing expenses) stemming from a favorable shift from lower margin revenue, such as Ag/GMO sales, to higher margin antibody and food safety revenue. For the quarter ended December 31, 2007, gross profit totaled $4.4 million, as compared to $3.9 million for the same period in 2006. Gross profit margins were 60.5% for the fourth quarter of 2007 compared to 55.8% for the same period in 2006.

SG&A expenses were $3.3 million in the fourth quarter of 2007 compared to $2.7 million in the fourth quarter of 2006. The Company incurred increased costs for the period associated with the launch of the antibody catalog. Research and development costs for the fourth quarter of 2007 were 10.4% of revenue compared to 9.6% in the prior year. Increases in R&D are associated with the Company's new products and services utilizing the GAT(TM) platform as well as ongoing development of the ethanol application of its bacteriophage technology for the selective control of lactic acid-producing bacteria.

Pre-tax income for the fourth quarter of 2007 totaled $409,000, compared to $650,000 for the prior year's fourth quarter. Net income for the quarter was $166,000, or $0.01 per diluted share, compared to $491,000, or $0.02 per diluted share, in the fourth quarter last year. Diluted shares totaling 20.8 million and 20.2 million were used in the computations for the years 2007 and 2006, respectively.

For the full year 2007, total revenue increased 7% to $27.2 million, compared to $25.5 million for 2006. Revenue gains were driven by antibody sales, which increased 29% year-over-year, and food pathogen test kit sales, which increased 22%, as compared to 2006. These gains were offset by a 44% decrease in the Company's Ag/GMO product line in 2007 as compared to 2006, in keeping with the ongoing and expected diminishment of that line of business.

Gross margins were 60.4% for the full year 2007 compared to 54.1% for 2006.

Research and development costs for full year 2007 were 10.8% of revenues compared to 10.3% for 2006.

SG&A costs for full year 2007 were 44% of revenues compared to 42% for 2006. During 2007, the Company incurred additional sales and marketing expense associated with the launch of the new antibody catalog.

Pre-tax income for full year 2007 totaled $1.8 million, compared to $966,000 for the same period in 2006. Net income for full year 2007 was $860,000, or $0.04 per diluted share, compared to $684,000, or $0.03 per diluted share, for last year. Diluted shares totaling 20.6 million and 20.1 million were used in the computations for the years 2007 and 2006, respectively.

Antibody Products

Antibody revenues increased by 28% to $3.8 million in the fourth quarter of 2007 compared to the same period in 2006 as the GAT platform continues to expand. For full year 2007, antibody revenues increased 29% over 2006.

Food Safety Products

Food pathogen revenues were up 21%, to $1.4 million for the fourth quarter of 2007 compared to the same period in 2006. Food pathogen sales increased 22.3% as the Company continues to gain traction with its new RapidChek(R) SELECT(TM) for Salmonella. The Company continued to actively recruit and train new international distributors during the quarter.

The Company has gained 14 new accounts on the Lumitester(TM) hygiene monitoring programs. Unlike competitive methods on the market, the Lumitester(TM) platform allows users to get more actionable information on the performance of their cleaning and sterilization programs in all aspects of their housekeeping and personal hygiene programs. The Company believes Lumitester(TM) is complementary to the RapidChek(R) line of food pathogen tests and will deliver additional sales synergies.

U.S. Ag-GMO product sales were down 64% for the fourth quarter of 2007 as compared to last year's fourth quarter, and down 44% for the full year of 2007. This continues an ongoing decline in this line of business.

Water and Environmental Products

Water and environmental products revenue increased 10% to $1.3 million for the quarter ended December 31, 2007, compared to the same period in 2006, but declined 2% for the full year of 2007.

Industrial Biofermentation

During the fourth quarter, SDI continued the development of its bacterophage technology for application in the production of ethanol from corn. The Company hired Energetix LLC as its consultant and is actively pursuing technology scale up and demonstration in fully commercial ethanol plants as early as the third quarter of this year. The company is targeting several large ethanol producing plants for further testing. The Company's joint development program with POET Energies has been suspended.

"We remain excited about our phage technology and confident it can bring significant value to the industrial bio-fermentation industry," Mr. Knight commented. "We are considering several opportunities for scale up which could be implemented in the next four to six months, including application in an operational corn ethanol facility."

Balance Sheet

The Company had $13.0 million in cash as of December 31, 2007 compared to $10.9 million as of December 31, 2006. The Company's current ratio (current assets divided by current liabilities) was 8 to 1. Stockholders' equity at December 31, 2007 was $37.1 million.

Conference Call

A conference call to review fourth quarter and full year 2007 results is scheduled for 4:30 p.m. Eastern Time on February 28, 2008. The dial-in number for the live conference call will be 877-407-8031 (201-689-8031 outside the U.S.). A live webcast of the conference call will be available on the Company's website,, as well as For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on February 28, 2008 through 11:59 p.m. on February 29, 2008. To listen to the telephone replay, dial 877-660-6853 (201- 612-7415 outside the U.S.) and enter account number 286 and conference ID 275460.

Annual Stockholders Meeting

The Company will hold its 2008 Stockholders Meeting on June 17, 2008.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based, discovery and detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying core competencies and innovative technologies in all aspects of antigen design, high throughput production and assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic, information and discovery needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the research, human/animal diagnostics, and pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project" "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.



(in thousands, except share and per share data)


December 31, December 31,

2007 2006


Current Assets :

Cash and cash equivalents $12,988 $ 10,892

Receivables, net 4,110 3,678

Inventories 4,204 3,178

Deferred tax asset 1,201 831

Other current assets 521 492

Total current assets 23,024 19,071

Property and equipment, net 5,481 4,058

Other assets 7 3

Deferred tax asset 7,389 8,484

Intangible assets, net 6,048 6,337

Total assets $41,949 $ 37,953


Current Liabilities :

Accounts payable $569 $541

Accrued expenses 1,866 1,455

Deferred revenue 5 133

Current portion of long term debt 611 211

Total current liabilities 3,051 2,340

Long-term debt 1,640 351

Non-current taxes payable 130 -

Total non-current liabilities 1,770 351

Stockholders' Equity:

Preferred stock, $.01 par value, 20,920,648

shares authorized, no shares issued or

outstanding - -

Common stock, $.01 par value, 35,000,000

shares authorized, 20,410,540 and 20,192,402

issued and outstanding at December 31, 2007

and December 31, 2006, respectively 205 202

Additional paid-in capital 39,594 38,605

Accumulated deficit (2,830) (3,690)

Cumulative translation adjustments 159 145

Total stockholders' equity 37,128 35,262

Total liabilities and stockholders'

equity $41,949 $ 37,953

The accompanying notes are an integral part of these statements.



(in thousands, except share and per share data)


Three Months Twelve Months

Ended December 31, Ended December 31,

2007 2006 2007 2006

Revenues $7,271 $6,990 $27,207 $25,522


Manufacturing 2,875 3,088 10,766 11,721

Research and

development 754 671 2,938 2,630

Selling, general and

administrative 3,329 2,692 11,990 10,591

Loss o

SOURCE Strategic Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
4. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. Genstar Names Michael Hurt to Its Strategic Advisory Board
7. Pharsight Expands Strategic Consulting Services Team
8. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
9. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
10. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
(Date:7/31/2020)... ... July 29, 2020 , ... ... top radiation centers in 16 countries, has reached its 20th anniversary of worldwide ... in routine use at top universities including University of Pennsylvania, University of Michigan, ...
(Date:7/22/2020)... ... 2020 , ... Join experts from Reed Tech , Gary Saner, Sr. ... one hour live webinar on Thursday, August 13, 2020 at 11am EDT ... medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical device ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new technology ... technology of its kind on the market and we were pleased that the IFT ... of traditional cultured ingredients, creating a natural way to extend the shelf life and ...
(Date:7/18/2020)... ... 17, 2020 , ... dicentra , a leading Contract ... industries, is pleased to announce that Charles Galea has joined its clinical trials ... is an accomplished and results-driven sales executive with over 10 years of expertise ...
Breaking Biology Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... ... that an extensive third-party assessment of the company’s security practices has been completed. ... federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them ...
(Date:8/26/2020)... ... August 25, 2020 , ... Catalent, the ... biologics, cell and gene therapies, and consumer health products, today announced that two ... Conference & Expo, taking place between Aug. 31 – September 4, 2020. , ...
(Date:8/21/2020)... Mass. (PRWEB) , ... August 18, 2020 , ... ... approaches to cell therapy, today announced that the U.S. Food and Drug Administration ... of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of ...
Breaking Biology News(10 mins):